87 related articles for article (PubMed ID: 24533712)
1. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.
Khrunin AV; Khokhrin DV; Moisseev AA; Gorbunova VA; Limborska SA
Pharmacogenomics; 2014 Feb; 15(3):329-37. PubMed ID: 24533712
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].
Кhokhrin DV; Khrunin AV; Ivanova FG; Moiseev AA; Gorbunova VA; Limborskaia SA
Mol Gen Mikrobiol Virusol; 2013; (4):6-9. PubMed ID: 24645271
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Khrunin AV; Moisseev A; Gorbunova V; Limborska S
Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
[TBL] [Abstract][Full Text] [Related]
5. Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.
van Huis-Tanja L; Kweekel D; Gelderblom H; Koopman M; Punt K; Guchelaar HJ; van der Straaten T
Pharmacogenomics; 2013 Dec; 14(16):2005-12. PubMed ID: 24279855
[TBL] [Abstract][Full Text] [Related]
6. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.
Dumontet C; Landi S; Reiman T; Perry T; Plesa A; Bellini I; Barale R; Pilarski LM; Troncy J; Tavtigian S; Gemignani F
Bone Marrow Transplant; 2010 Aug; 45(8):1316-24. PubMed ID: 19966851
[TBL] [Abstract][Full Text] [Related]
14. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Liang KH; Lin CC; Yeh CT
Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
16. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.
Khrunin A; Ivanova F; Moisseev A; Khokhrin D; Sleptsova Y; Gorbunova V; Limborska S
Pharmacogenomics; 2012 Jan; 13(2):171-8. PubMed ID: 22188361
[TBL] [Abstract][Full Text] [Related]
19. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
Medeiros R; Pereira D; Afonso N; Palmeira C; Faleiro C; Afonso-Lopes C; Freitas-Silva M; Vasconcelos A; Costa S; Osório T; Lopes C
Int J Clin Oncol; 2003 Jun; 8(3):156-61. PubMed ID: 12851839
[TBL] [Abstract][Full Text] [Related]
20. 'Genetic profiling' and ovarian cancer therapy (review).
Vella N; Aiello M; Russo AE; Scalisi A; Spandidos DA; Toffoli G; Sorio R; Libra M; Stivala F
Mol Med Rep; 2011; 4(5):771-7. PubMed ID: 21687948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
